This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

UCB Announces Data On Cimzia® (certolizumab Pegol) For Patients With Moderate To Severe Rheumatoid Arthritis At American College Of Rheumatology 2012 Congress

Adverse events (AE) were comparable among the three groups and the most common serious AEs belonged to the system organ class infections and infestations (4.3% in 200 mg every two week group and none in 400 mg every four week or placebo groups).

*Certolizumab pegol in combination with methotrexate is approved in the European Union as a maintenance regimen of 200 mg every two weeks. The certolizumab pegol dosing regimen of 400 mg every four weeks is not approved in the European Union.

Improved Long-Term Household Productivity and Increased Participation in Family, Social and Leisure Activities

Presentation Title: Long-term Benefits of 4-Weekly Certolizumab Pegol and Monotherapy on Household Productivity and Social Participation in Rheumatoid Arthritis: 5 year Results from an Open-Label Extension Study

    • Monday, November 12, 2012: 9:00 AM-6:00 PM
    • Location: WCC: Poster Hall (Hall B)

Five year results from an open-label extension study of patients originally enrolled in two pivotal trials demonstrated improved household productivity and increased participation in social activities in RA patients treated with certolizumab pegol who continued from baseline over the five years of the study period. The study examined 235 patients taking 400 mg* of certolizumab pegol once every four weeks, as a monotherapy or in combination with MTX or DMARDs, over five years.  Household productivity and social participation were assessed through the validated RA-specific Work Productivity Survey.

In both populations analyzed, a reduction in the number of days missed of household work per month was observed over 24 weeks and continued to decrease over time (from baseline 7.4 and 11.1 mean days in the combination and monotherapy groups, respectively, to 1.2 and 1.4 mean days, respectively). Increased participation in social activities was reported in both populations, with a decrease in the number of days missed per month (from baseline 4.4 and 6.2 mean days in the combination and monotherapy groups, respectively, to 0.4 and 0.2 days, respectively).

3 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs